Providing for human health

High-quality specialized products and services

Quality & Responsibility
Customer first, integrity & honesty, scientific rigor

Passionate Struggle, Collaborative Efficiency, Learning & Enterprising

scroll down


Wuhan RS Pharmaceuticals Co., Ltd. was founded in April 2009, located in Gedian Economic and Technological Development Zone, Ezhou City, Hubei Province, is a modernized generic drug research and development and API production enterprise in line with FDA and cGMP, with an investment of RMB 300 million in the first phase, covering an area of 172 acres, and 200 acres in the second phase, totaling 372 acres. The first phase construction was completed at the end of December 2012, and the trial production started in April 2013. In October 2013, we obtained the drug production license of Wuhan Ruisheng Pharmaceutical Co., Ltd. and the 2010 GMP certificates of Atorvastatin Calcium and Fasudil Mesylate. The first phase of the construction includes a pilot plant for pharmaceutical raw materials, a multi-functional plant, a vertical flow synthesis plant, a hydrogenation plant and its supporting utility works, such as boiler room, engineering building and sewage treatment station. The company currently employs more than 130 people, and the number of employees is expected to exceed 300 after the completion of Phase II construction.

2009 year


3000 ten thousand yuan

Registered capital

372 classifier for fields


300 +

No. of employees

  • Innovative directions
    Innovative directions
    Wuhan RS Pharmaceuticals is the center of gravity of generic drug research and development invested and constructed by the Group, always focusing on the introduction of research and development talents and echelon construction, with leading research and development capability in the industry; coupled with the Group's rich experience in the clinical department of new drugs, the registration department, and the preparation and transformation of the company, which makes Wuhan Ruisheng Pharmaceuticals R & D and results of the transformation continue to accelerate.
  • Technology platform
    Technology platform
    At present, we mainly have H-FLOW fully automatic hydrogenation reactor, kilogram-scale integrated silicon carbide reactor, coil reactor, DP series double plunger high-pressure constant-flow infusion pump, double injection high-pressure/low-pressure constant-flow infusion pump, full-automatic dosing and calibration system, full-automatic back-pressure valve, and micro-reaction full-automatic liquid-liquid synthesizing system, etc. as well as related accessories. The basic conditions required for fluid chemistry process development have been initially formed.
  • Patent certificate
    Patent certificate
    Patent certificates for fasudil derivatives and their preparation methods, vitamin D analogs and their preparation methods and medicinal uses, a menthyl ornithine crystalline IV and its preparation method, a posaconazole liquid suspension and its preparation method, and many others.
  • Innovative R&D
    RS Pharmaceuticals has introduced a large number of domestic and foreign high-quality talents, while gradually cultivating its own R & D strength, and constructed a full set of R & D system from small test, pilot test to production. The company adopts domestic and foreign high-quality production facilities and equipment, advanced QC laboratory testing instruments...



    Sun Bing, secretary of Ezhou Municipal Party Committee, investigates Wuhan RS Pharmaceuticals Co., Ltd

    Aug 22,2022

    Sun Bing, secretary of Ezhou Municipal Party Committee, investigates Wuhan RS Pharmaceuticals Co., Ltd

    On April 5, Sun Bing, Secretary of the CPC Municipal Committee of Ezhou and Commander of Ezhou Municipal Prevention and Control Headquarters, accompanied by Zhao Benli, Secretary of the Municipal Commission for Discipline Inspection, Lu Hui, Deputy Mayor, Peng Bo and Gao Fei, Director of the Management Committee of Gedian Development Zone, went to ---- Wuhan RS Pharmaceuticals Co., Ltd a subsidiary of the CMC business segment of the Group
    Huanggang ZY synthetic nicotine project phase I environmental assessment for the first time

    Jun 07,2021

    Huanggang ZY synthetic nicotine project phase I environmental assessment for the first time

    According to the provisions of The State Council Decree No. 682 "Regulations on Environmental Protection Management of Construction Projects", the Environmental Impact Assessment Law of the People's Republic of China "and the requirements of the Ministry of Ecology and Environment Decree No. 4" Measures for Public Participation in Environmental Impact Assessment ", Huanggang ZY Biotechnology Co., Ltd. has disclosed the information related to the first phase of the project with an annual output of 300 tons of synthetic nicotine as follows:

    May 02,2018

    The first poetry recitation competition and May 4th Youth outreach activities

    Aug 02,2017

    There are reports of fire drill in Wuhan Pharmaceutical industry